The US Food and Drug Administration is asking an advisory committee to vote on whether the pharmacokinetic and pharmacodynamic data of ARS Pharmaceuticals, Inc.’s intranasal epinephrine are “sufficiently robust” compared to epinephrine injection products to support a favorable benefit-risk assessment of this novel route of administration.
The agency did not indicate how it comes down on the question in a